Melanoma xenograft weights (29 days after tumor challenge) were significantly lower in mice given intravenous treatment with CSPG4 IgE compared with no antibody or non-specific isotype IgE control groups (Fig. 7b, left). This evidence concerns the gene CSPG4 and neoplasm.